

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with application dated <b>September 23, 2015,</b>
1. Henry Ford Wyandotte Hospital	3. License No. 21-12930-01 is renewed in its entirety to read as follows:
2. 2333 Biddle Avenue	4. Expiration Date: <b>March 31, 2026</b>
Wyandotte, Michigan 48192	5. Docket No. 030-02140 Reference No.

- |   |   |  |
|---|---|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form  | 8. Maximum amount that licensee may possess at any one time under this license |
| A. Any byproduct material permitted by 10 CFR 35.100  | A. Any  | A. As needed   |
| B. Any byproduct material permitted by 10 CFR 35.200  | B. Any  | B. As needed   |
| C. Any byproduct material permitted by 10 CFR 35.300  | C. Any  | C. 1 curie   |
| D. Any byproduct material permitted by 10 CFR 31.11   | D. Prepackaged kits   | D. 5 millicuries   |
| E. Iodine-125 as permitted by 10 CFR 35.400           | E. Sealed sources (Amersham Health (d/b/a GE Healthcare), or Medi-Physics, Inc. (d/b/a Oncura, Inc.) Model 6711 and Bard Brachytherapy Model STM1251) | E. 250 millicuries   |

## 9. Authorized Use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic or therapy procedure permitted by 10 CFR 35.300.
- D. In vitro studies.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License No.  
21-12930-01Docket or Reference No.  
030-02140

Amendment No. 45

- E. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

CONDITIONS

10. A. Licensed material may be used or stored at the licensee's facilities located at 2333 Biddle Avenue, Wyandotte, Michigan.
- B. Licensed material listed in Subitem No. 6.B. may be used or stored at the licensee's facilities located at Henry Ford Health Center – Brownstown, 23050 West Road, Brownstown Township, Michigan.
11. The Radiation Safety Officer (RSO) for this license is Alan M. Jackson, M.S., CHP.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for the material and medical uses:

<u>Authorized User</u>	<u>Material and Use</u>
James J. Kochkodan, M.D.	10 CFR 35.100, 35.200, and 31.11.
K. P. Bartold, M.D.	10 CFR 35.100, 35.200, and 35.300.
Sophia Roumanis, M.D.	10 CFR 35.100, 35.200, and 35.300.
Jerry W. Drake, M.D.	10 CFR 35.100, 35.200, and 35.300.
Dong Hyuck Kim, M.D.	10 CFR 35.100, 35.200, and 31.11.
John H. Finger, M.D.	10 CFR 35.100, 35.200, and 35.300.
Donald J. Conn, M.D.	10 CFR 35.100, 35.200, and 35.300.
Rob Allen Reed, M.D.	10 CFR 35.100 and 35.200.
Deepak Pradhan, M.D.	10 CFR 35.400.
Bruno F. Borin, D.O.	10 CFR 35.100 and 35.200.
Vito A. Casano, M.D.	10 CFR 35.100 and 35.200.
Michael F. Zydeck, M.D.	10 CFR 35.100 and 35.200.
Ibrahim Aref, M.D.	10 CFR 35.400.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License No.  
21-12930-01Docket or Reference No.  
030-02140

Amendment No. 45

Michael Arsenault, D.O. 10 CFR 35.100, 35.200 and 35.300.

Kevin J. Berlin, D.O. 10 CFR 35.200.

Charles Terrell Cash, III, M.D. 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131).

Jessica Marie Kaniowski, M.D. 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131).

Ronald Joseph Meade, M.D. 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131).

Geling T. Sauter, M.D. 10 CFR 35.100, 35.200 and 35.300.

David James Rossow, M.D. 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131).

Sharif M. Kershah, M.D. 10 CFR 35.100 and 35.200.


Gregory D. Olson, M.D. 10 CFR 35.100 and 35.200.

13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated September 23, 2015 (ML15275A432)
- B. Letter dated January 25, 2016 (ML16025A212)

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date MAR 11 2016

By

  
Frank P. D. Tran  
Materials Licensing Branch  
Region III